Enveda raises $311M for AI drug discovery from nature

enveda, a biotech startup founded in 2019 by viswa colluru, uses ai to discover new drugs in plants and microbes. the company raised $311 million in series e funding, led by catalio capital management, at a $2 billion valuation, doubling its valuation from 12 months ago. enveda is currently testing several ai-discovered drugs in patients, including treatments for severe skin conditions and weight loss. this funding will help enveda advance more nature-derived ai drugs into clinical trials, a crucial step towards fda approval and commercialization.